A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > REGULATORY
REGULATORY
- CSIMC Nixes Industry’s Call for “Hold” on Further Price Cuts on Long-Listed Drugs
December 6, 2012
- Japan “Not Ready” for Reference Price System at the Present Time: Prof. Sakamaki of Meijo University
December 6, 2012
- CSIMC Subcommittee Agrees on Introduction of New Price-Cut Rule for Long-Listed Products
December 6, 2012
- MHLW Asks to Revise Precautions Section of Package Inserts for Poteligeo, Telavic
December 6, 2012
- PFSB to Initiate Epidemiological Study of Vaccination and Sudden Infant Death
December 5, 2012
- PAFSC’s 1st Committee on New Drugs Recommends Orphan Drug Designation for 2 Products Including Kyowa Kirin’s Cinacalcet
December 4, 2012
- 3 Products Including Daiichi Sankyo’s Calblock Classified as Category I
December 4, 2012
- PAFSC’s 1st Committee Recommends Approval for Factor Xa Inhibitor Apixaban
December 3, 2012
- MHLW to Conduct Field Study for Japanese Version of “Compassionate Use” System
December 3, 2012
- Price Agreement Rates for JPWA, NPhA Member Companies Just 11% at End of September: Distribution Council
December 3, 2012
- Price Agreement Rate at 43.5% in September; Down 3.2 Points from 2 Years Ago: MHLW Survey
December 3, 2012
- 6 APIs Including Taiho’s Aloxi IV Infusion Bag Added to NHI Price List
December 3, 2012
- PAFSC’s 2nd Committee Recommends Approval for Allegra-Pseudoephedrine Combination Drug Dellegra
November 30, 2012
- Expert Subcommittee to Discuss New Targets for Generic Drugs at Next Meeting
November 30, 2012
- MHLW Safety Info. Calls for Caution on Pulmonary Hypertension Associated with Glivec
November 30, 2012
- FPMAJ Chairman Naito Nudges CSIMC to Discuss Perpetuation of Premiums, Abolishment of Special Price Cuts for Long-Listed Drugs
November 29, 2012
- Switch OTC Version of Ebastine Recommended for Approval
November 28, 2012
- BIKEN Exits New Flu Vaccine Development Project, MHLW to Invite Other Makers
November 26, 2012
- LDP Policy Statement Calls for Perpetuation of New Drug Premium, Promotion of Switch-OTC Drugs
November 26, 2012
- MHLW Approves Additional Indications for 3 APIs/5 Products, Including Botox
November 26, 2012
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…